Lawyering-up News Research integrity

Zauli and University of Ferrara announce libel suit, criminal prosecution against me

My report from just a week ago, about the data irregularities in papers from Italian  haematologist and cancer researcher Giorgio Zauli provoked a response of a legal threat, of both criminal and civil prosecution. Zauli is namely rector of the University of Ferrara, and he issued this threat in this official capacity, acting for his Italian university. I was already made aware of Zauli’s threats of suing me from a first-hand source, and my site was indeed accessed by Italian State prosecutor’s office the day after I published my article about Zauli’s flawed cytometry and other problematic data in research papers he mostly co-authored with Ferrara’s Head of Department, Paola Secchiero. This letter from Zauli below, which reached me today per certified mail, is the more bizarre due to the fact the university denied any knowledge of Zauli’s legal threats (see the update here).

In any case, here is the letter, on the headed paper of the University of Ferrara, which even paid the postage. Zauli and his university apparently assume that their research publications and public institutional profiles are personal data, protected by EU privacy regulations. Maybe rector Zauli is confused at to where the Latin-derived word “publications” comes from. It’s from “public” and certainly not from “pubic”, hence definitely not his sphere of personal privacy. Though his publications could profit from some data integrity hygiene. In any case, the Ethics Commission of University of Ferrara will convene on June 1st to decide what to do about the publicly available PubPeer evidence I reported about. The scanned original is here. Please disseminate widely. head

 

I, prof. Giorgio Zauli, currently pro-tempore Rector of the University of Ferrara, hereby report that on May 15th 2018 the website “ForbetterScience” published a post created by Leonid Schneider – independent science journalist – reporting fake and unproven informations on alleged incorrectness of some scientistic publications of the undersigned.

The above mentioned “ForbetterScience” post is visible in and linked to the following websites:

https://forbetterscience.com/2018/05/15/flawed-cytometry-of-rector-giorgio-zauli/#more-23763

[etc]

The reported statements are totally unfounded and have been the object of a criminal complaint made by the undersigned to the prosecutor’s office of the Republic of Ferrara on 16th May 2018.

Further legal actions will follow in both criminal and civil matters.

In order to defend the integrity of the undersigned, also in light of the public role held, I request the immediate removal of the above mentioned posts from your search engine both known and unknown in accordance to the following law sentence:

JUDGMENT OF THE COURT (Grand Chamber) 13 May 2014 Personal data — Protection of individuals with regard to the processing ofsuch data — Directive 95/46/EC — Articles 2, 4, I2 and 14 — Material and territorial scope — Internet search engines — Processing of data contained on websites — Searching for, indexing and storage of such data — Responsibility of the operator of the search engine Establishment on the territory of a Member State — Extent of that operator’s obligations and of the data subject’s rights Charter of Fundamental Rights of the European Union Articles 7 and 8, and whose conclusions are reported below:

On those grounds, the Court (Grand Chamber) hereby rules:

1. Article 2(b) and (d) of Directive 95/46/EC of the European Parliament and ofthe Council of 24 October I995 on the protection of individuals with regard to the processing of personal data and on the free movement of such data are to be interpreted as meaning that, first, the activity of a search engine consisting in finding information published or placed on the internet by third parties, indexing it automatically, storing it temporarily and, finally, making it available to internet users according to a particular order of preference must be classified as ‘processing of personal data’ within the meaning of Article 2(b) when that information contains personal data and, second, the operator of the search engine must be regarded as the ‘controller’ in respect of that processing, within the meaning of Article 2(d).

2. Article 4(1) (a) of Directive 95/46 is to be interpreted as meaning that processing of personal data is carried out in the context of the activities of an establishment of the controller on the territory of a Member State, within the meaning of that provision, when the operator ofa search engine sets up in a Member State a branch or subsidiary which is intended to promote and sell advertising space offered by that engine and which orientates its activity towards the inhabitants of that Member State.

3. Article 12(b) and subparagraph (a) of the first paragraph of Article 14 of Directive 95/46 are to be interpreted as meaning that, in order to comply with the rights laid down in those provisions and in so far as the conditions laid down by those provisions are in fact satisfied, the operator of a search engine is obliged to remove from the list of results displayed following a search made on the basis of a person ’s name links to web pages, published by third parties and containing information relating to that person, also in a case where that name or information is not erased before hand or simultaneously from those web pages, and even, as the case may be, when its publication in itself on those pages is lawful.

4. Article 12(b) and subparagraph (a) of the first paragraph of Article 14 of Directive 95/46 are to be interpreted as meaning that, when appraising the conditions for the application of those provisions, it should inter alia be examined whether the data subject has a right that the information in question relating to him personally should, at this point in time, no longer be linked to his name by a list of results displayed following a search made on the basis of his name, without it being necessary in order to find such a right that the inclusion of the information in question in that list causes prejudice to the data subject. As the data subject may, in the light of his fundamental rights under Articles 7 and 8 of the Charter, request that the information in Question no longer be made available to the general public on account of its inclusion in such a list of results, those rights override, as a rule, not only the economic interest of the operator of the search engine but also the interest of the general public in having access to that information upon a search relating to the data subject’s name. However, that would not be the case if it appeared, for particular reasons, such as the role played by the data subject in public life, that the interference with his fundamental rights is justified by the preponderant interest of the general public in having, on account of its inclusion in the list of results, access to the information in question.

If you do not proceed to comply with this request immediately, I shall be forced to take legal actions against this company.

Best regards
Ferrara, May 17th 2018

signature


Update 28.05.2018. The comment section below overflows with new evidence posted by “Zebedee”. Which prompted another one of my readers to contribute something on one of those papers, on a Zauli-coauthored Ultimo et al Oncotarget 2017 by his Ferrara colleague Luca Neri:

Oncotarget 2017

 


Update 5.06.2018. The Ethics Commission of University of Ferrara now issued a press release. Law professor Andrea Pugiotto and colleagues declare all the evidence submitted by me is inadmissible, because only those employed or studying at the university can report suspected misconduct. Instead, Zauli himself apparently requested this inadmissibility decision, and possibly also raised a complaint against me with the Ethics Commission. Indeed, the university keeps refusing to comment on the criminal and civil actions it announced against me.

This is the translated press release:

On 1 June 2018, at 14:30, the Ethics Commission of the University of Ferrara met to deliberate, as a preliminary ruling, on the admissibility of the petition presented by Mr. Leonid Schneider (protocol No. 64072 – 16 May 2018) and the documentation in response filed by Prof. Giorgio Zauli (protocol No. 66968 -1 June 2018).
2. From a subjective point of view, the petition presented by Mr Leonid Schneider is inadmissible, for the absorbing reason of the applicant’s lack of legitimacy to act before this Commission.
In fact, the Ethics Committee can be contacted or reported any behaviour contrary to the University Code of Ethics by “professors, researchers, administrative staff, students and any other University member” (Article 14, paragraph 1), including in the residual category “all those who for various reasons spend periods of research, teaching and study at the University” (thus the Preamble to the Code of Ethics).

3. The documentation filed by Prof. Giorgio Zauli, with explicit request to be examined at the first possible session, is intended by the Commission as a request for an opinion on the application of the University Code of Ethics to the case described (Article 14, 1 ° paragraph, letter c).
The applicant’s legitimacy to act is certain, just as the application meets the criteria for its taking into consideration.

Update II, 5.06.2018. Zauli now contacted on behalf of University of Ferrara… TWITTER. I received this message from twitter legal department, with this official letter by Zauli  attached (so, if my Twitter accounts gets removed, thank Zauli!):

“We are writing to inform you that Twitter has received official correspondence attached regarding your Twitter account, @schneiderleonid.
The correspondence claims that the following Tweet, is illegal:
https://twitter.com/schneiderleonid/status/996835333164630016

Twitter has not taken any action on the reported content at this time. We are only writing to inform you of content posted to your account which has been mentioned in a complaint.
We may be obligated to take action regarding the content identified in the complaint in the future. Please let us know by replying to this email as soon as possible if you decide to voluntarily remove the content identified on your account”.

 


 

 

 

Donate!

If you are interested to support my work, you can leave here a small tip of $5. Or several of small tips, just increase the amount as you like. Your generous patronage of my journalism, however small it appears to you, will greatly help me with my legal costs.

€5,00

58 comments on “Zauli and University of Ferrara announce libel suit, criminal prosecution against me

  1. Smut Clyde

    The above-mentioned “ForbetterScience” post is visible in and linked to the following websites…
    Facebook? Google?
    I am not sure that Rector Professor Zauli quite understands how the Internet works.

    Like

  2. Smut Clyde

    In order to defend the integrity ofthe undersigned, also in light ofthe public role held, I request the immediate removal of the above mentioned posts from your search engine both known and unknown in accordance to the following law sentence:

    Leonid was really Google all along. I should have realised.

    Like

  3. Zebedee

    Giorgio Zauli does need to explain the highlighted data which appears in the scientific record.

    Presently there is a breach of scientific integrity, which needs to be repaired.

    Liked by 1 person

  4. Zebedee

    While he is at it Giorgio Zauli should sue Pubpeer.

    https://pubpeer.com/search?q=zauli

    Like

  5. Zebedee

    Carlo Maria Croce, who is faculty at the University of Ferrara, is suing the New York Times.
    https://www.courthousenews.com/wp-content/uploads/2017/05/CroceNYT.pdf
    after it published this article. https://www.nytimes.com/2017/03/08/science/cancer-carlo-croce.html

    Again, while he is at it he should sue Pubpeer: https://pubpeer.com/search?q=carlo+croce

    Like

    • Peentous

      I find it funny that the lawsuit states all the “achievements” made by Dr. Croce – i wonder what is the link between found a gene that now has a drug and falsification of data? If you made one you cannot make another one? Are those things mutually exclusive?
      So, according to the lawyers if one has not published tons of articles or high-impact papers is he more prone to falsification? Dear lawyers, those two things go (sometimes) along, i.e. more research, less quality (a very mild way of saying false data)

      Like

  6. Hi Leonid
    First, of all: you got a nice Streisand effect going on there. 🙂
    Second, and a little more importantly, that laughable “legal threat” (notice the scare quotes) should not bother you or anybody else in the least. That simple deserves the familiar Popehat response: “Snort my taint”
    Keep doing what you have been doing.

    Third, and most importantly “Alles Gute für Morgen, du weisst ja ‘vor Gericht und auf hoher See..’ ”

    Cheers, Oliver

    Liked by 1 person

    • Smut Clyde

      I recall that Leonid and Popehat are not on good terms, as they are both irascible individuals who sometimes send inflammatory tweets.

      Like

    • Smut Clyde

      I am not a lawyer so I try not to advise other people on which legal threats they should ignore.
      As well as not being a lawyer, I am not the person who experiences the consequences if that advice turns out to be wrong.

      Like

  7. Pingback: Effetto Streisand - Ocasapiens - Blog - Repubblica.it

  8. Elia Marin

    Not long ago, while speaking about his “transparent” administration, he said that Italian University is really healthy.

    http://lanuovaferrara.gelocal.it/ferrara/cronaca/2018/05/09/news/unife-e-trasparente-sulle-autorizzazioni-1.16816294

    Like

  9. zebedee

    It is becoming a Dario Fo farce! What would be a good title?

    Like

  10. Maybe you will find a pig’s head outside your house soon….
    We need an international organization with responsibility and power to do something with all the problems in science. Like WADA. If they have it in sport, why not in science?! An organization which can overrule all the corrupted research institutes and ask for raw data and take decisions regarding retractions. The system (or lack of) we have today is not working and is an invitation to research misconduct and fraud.

    I fully support your work and admire your courage, Leonid.

    Like

  11. Pingback: Boletim de Notícias: Os encontros e desencontros da ciência com o glúten | Direto da Ciência

  12. Zebedee

    3 more prominent haematologists:-

    C. Gambacorti-Passerini: https://pubpeer.com/search?q=gambacorti-passerini
    L. Cocco: https://pubpeer.com/search?q=lucio+cocco
    B. Venerando: https://pubpeer.com/search?q=venerando

    Like

  13. Leonid hit a nerve. Way to go. Congrats

    Like

  14. First Italian newspaper reports: http://lanuovaferrara.gelocal.it/ferrara/cronaca/2018/05/26/news/scambi-d-accuse-sulle-ricerche-del-rettore-zauli-1.16886149
    HT:

    Like

  15. Zebedee

    Oncotarget. 2017 Apr 4;8(14):23213-23227. doi: 10.18632/oncotarget.15542.
    PI3K isoform inhibition associated with anti Bcr-Abl drugs shows in vitro increased anti-leukemic activity in Philadelphia chromosome-positive B-acute lymphoblastic leukemia cell lines.
    Ultimo S1, Simioni C1, Martelli AM2, Zauli G1, Evangelisti C3, Celeghini C4, McCubrey JA5, Marisi G6, Ulivi P6, Capitani S1,7, Neri LM1.
    Author information

    1 Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, Italy.
    2 Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.
    3 Institute of Molecular Genetics, Rizzoli Orthopedic Institute, National Research Council, Bologna, Italy.
    4 Department of Life Sciences, University of Trieste, Trieste, Italy.
    5 Department of Microbiology and Immunology, Brody School of Medicine, East Carolina University, Greenville, NC, USA.
    6 Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
    7 LTTA Center, University of Ferrara, Ferrara, Italy.

    Figure 2.

    Like

  16. Zebedee

    Oncotarget. 2017 Apr 4;8(14):23213-23227. doi: 10.18632/oncotarget.15542.
    continued.

    Figures 2B and 5.

    Like

  17. Zebedee

    Oncotarget. 2016 Aug 23;7(34):55690-55703. doi: 10.18632/oncotarget.10984.
    Healthy CD4+ T lymphocytes are not affected by targeted therapies against the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia.
    Alameen AA1,2, Simioni C1, Martelli AM3, Zauli G1, Ultimo S1, McCubrey JA4, Gonelli A1, Marisi G5, Ulivi P5, Capitani S1,6, Neri LM1.
    Author information

    1 Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, Italy.
    2 Department of Chemical Pathology, Faculty of Medical Laboratory Sciences, University of Khartoum, Khartoum, Sudan.
    3 Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.
    4 Department of Microbiology & Immunology, Brody School of Medicine, East Carolina University, Greenville, NC, USA.
    5 Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
    6 LTTA Center, University of Ferrara, Ferrara, Italy.

    Figure 5.

    Like

  18. Zebedee

    The Rector of the University of Ferrara might give the heads-up to the Rector of Bologna University about this recent paper.

    Oncotarget. 2016 Jan 12;7(2):1323-40. doi: 10.18632/oncotarget.6361.
    Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κB.
    Buontempo F 1, Orsini E 1, Lonetti A 2, Cappellini A 3, Chiarini F4,5, Evangelisti C 4,5, Evangelisti C 1, Melchionda F 2, Pession A 2, Bertaina A 6, Locatelli F 6, Bertacchini J 7, Neri LM 8, McCubrey JA 9, Martelli AM 1.

    Author information

    1 Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.
    2 Pediatric Oncology and Hematology Unit “Lalla Seràgnoli”, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy.
    3 Department of Human Social and Health Sciences, Campus Folcara, University of Cassino, Cassino, Italy.
    4 Muscoloskeletal Cell Biology Laboratory, IOR, Bologna, Italy.
    5 Institute of Molecular Genetics, National Research Council-Rizzoli Orthopedic Institute, Bologna, Italy.
    6 Department of Pediatric Hematology and Oncology, IRCCS Bambino Gesù Children’s Hospital, Rome, Italy.
    7 Department of Surgery, Medicine, Odontostomatology and Morphological Sciences, University of Modena, Modena, Italy.
    8 Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, Italy.
    9 Department of Microbiology and Immunology, School of Medicine, East Carolina University, Greenville, NC, USA.

    See: https://pubpeer.com/publications/EA520B289FB46E04CC46739C7A2850

    Like

  19. Zebedee

    Oncotarget. 2014 Oct 30;5(20):10034-47.
    Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivation.
    Simioni C 1, Cani A 1, Martelli AM 2, Zauli G 3, Tabellini G 4, McCubrey J 5, Capitani S 6, Neri LM 1.
    Author information

    1 Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, Italy.
    2 Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.
    3 Institute for Maternal and Child Health, IRCCS “Burlo Garofolo”, Trieste, Italy.
    4 Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
    5 Department of Microbiology and Immunology, Brody School of Medicine, East Carolina University, Greenville, NC, USA.
    6 Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, Italy. LTTA Center, University of Ferrara, Ferrara, Italy.

    Figure 4.

    Like

  20. Zebedee

    Oncotarget. 2015 Jul 10;6(19):17147-60.
    The novel dual PI3K/mTOR inhibitor NVP-BGT226 displays cytotoxic activity in both normoxic and hypoxic hepatocarcinoma cells.
    Simioni C 1,2, Cani A 1,2, Martelli AM 3, Zauli G 4, Alameen AA 1,5, Ultimo S 1, Tabellini G 6, McCubrey JA 7, Capitani S 1,2, Neri LM 1.
    Author information

    1 Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, Italy.
    2 LTTA Center, University of Ferrara, Ferrara, Italy.
    3 Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.
    4 Institute for Maternal and Child Health, IRCCS “Burlo Garofolo”, Trieste, Italy.
    5 Department of Chemical Pathology, Faculty of Medical Laboratory Sciences, University of Khartoum, Khartoum, Sudan.
    6 Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
    7 Department of Microbiology & Immunology, Brody School of Medicine, East Carolina University, Greenville, NC, USA.

    Figure 2D.

    Like

    • Zebedee

      Oncotarget. 2015 Jul 10;6(19):17147-60.
      continued.

      Figure 4A.

      Like

    • Smut Clyde

      I tried my hand at one of those positive / negative cancellation combinations of the two panels you showed, to confirm that they contain identical cells (no re-gating or anything), differing only in the criteria that define what proportion of cells fall into each quadrant.

      Like

  21. Zebedee

    Oncotarget. 2016 Nov 29;7(48):79842-79853. doi: 10.18632/oncotarget.13035.
    Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia.
    Simioni C 1, Ultimo S 1, Martelli AM 2, Zauli G 1, Milani D 1, McCubrey JA 3, Capitani S 1,4, Neri LM 1.
    Author information

    1 Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, Italy.
    2 Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.
    3 Department of Microbiology & Immunology, Brody School of Medicine, East Carolina University, Greenville, NC, USA.
    4 LTTA Center, University of Ferrara, Ferrara, Italy.

    Figure 2.

    Like

  22. Zauli: «Sono solo attacchi diffamatori e senza prove»

    Il rettore replica ai dubbi dei blogger che contestano la correttezza dei suoi studi «Ricerche vagliate da revisori internazionali, e chi accusa usa l’anonimato»

    http://lanuovaferrara.gelocal.it/ferrara/cronaca/2018/05/27/news/zauli-sono-solo-attacchi-diffamatori-e-senza-prove-1.16890347

    Like

  23. Pingback: O's digest con un grazie qua e là - Ocasapiens - Blog - Repubblica.it

  24. Pingback: L'insolita diffida dell'Università di Ferrara | di Sylvie Coyaud

  25. Zebedee

    Italian State prosecutor should turn his, or her, attention to Zauli. Why is the Italian State prosecutor trying to suppress scientific debate?

    Like

  26. Zebedee

    Luca Maria Neri.
    Oncogene (2002) 21, 7464 – 7470. Cdk9, a member of the cdc2-like family of kinases, binds to gp130, the
    receptor of the IL-6 family of cytokines.
    Giulia De Falco 1,2, Luca Maria Neri 3,4, Maria De Falco 5, Cristiana Bellan 1,2, Zailin Yu 6,
    Antonio De Luca 7, Lorenzo Leoncini 1 and Antonio Giordano*,1
    1 Sbarro Institute for Cancer Research & Molecular Medicine, College of Science & Technology, Temple University, Philadelphia,
    Pennsylvania, PA 19122, USA;
    2 Istituto di Anatomia e Istologia Patologica, Via delle Scotte, 6-53100 Siena, Italy;
    3 Dipartimento di Morfologia ed Embriologia, Sezione di Anatomia Umana, Universita di Ferrara, via Fossato di Mortara 66, 44100 Ferrara, Italy;
    4 Istituto di Citomorfologia Normale e Patologica del CNR, c/o IOR, via di Barbiano 1/10, 40137 Bologna, Italy;
    5 Dipartimento di Biologia Evolutiva e Comparata, Universita Federico II di Napoli, Italy;
    6 Jefferson Medical College, KCI Room
    376, 1020 Locust Street, Philadelphia, Pennsylvania, PA 19107, USA;
    7 Istituto di Anatomia Topografica, Seconda Universita
    di Napoli, Italy.

    See: https://pubpeer.com/publications/63C75C098EEC7CE710513771887233

    Like

  27. Ethics Code

    Actually, art. 14 does NOT say who is entitled to access the ethics committee, BUT just that university personnel is tighten to the code and that should access the committee wehnever they have doubts and report to the committee ay suspect violation.

    BUT art. 15 states that the commitee must monitor any violation and that it proceeds upon non-anonymous reports or EVEN upon its autonomous decision (comma4, lett c), WITHOUT specifyiing any limitation in the categories of people who can report.

    As I understand, they should proceed based on your report. But of course they don’t want.

    Like

  28. Pingback: Effetto Streisand, cont. - Ocasapiens - Blog - Repubblica.it

  29. Zebedee

    J Leukoc Biol. 2002 Jun;71(6):957-65.
    Selective up-regulation of phospholipase C-beta2 during granulocytic differentiation of normal and leukemic hematopoietic progenitors.
    Valeria Bertagnolo,* Marco Marchisio,,†,‡Sabina Pierpaoli, Maria Luisa Colamussi,Federica Brugnoli, Giuseppe Visani,§Giorgio Zauli,II and Silvano Capitani*

    *Signal Transduction Unit/Laboratory of Cell Biology, Section of Human Anatomy, Department of Morphology and Embryology, and # MIUR ICSI (Interdisciplinary Center for the Study of Inflammation), University of Ferrara, Italy; †Department of Biomorphology, University “G.D’Annunzio”, Chieti, Italy;‡
    Department of Pathology, UniformedServices University of the Health Sciences, Bethesda, Maryland;
    §L.A. Seragnoli Institute of Haematology, University of Bologna, Italy; and IIDepartment of Normal Human Morphology, University of Trieste, Italy.

    See: https://pubpeer.com/publications/2A182F8AAAA282DEEDB839CDCED21D

    Like

  30. Zebedee

    Clin Cancer Res. 2010 Mar 15;16(6):1824-33. doi: 10.1158/1078-0432.CCR-09-3031. Epub 2010 Mar 9.
    The oncogene DEK promotes leukemic cell survival and is downregulated by both Nutlin-3 and chlorambucil in B-chronic lymphocytic leukemic cells.
    Secchiero P 1, Voltan R 1, di Iasio MG 1, Melloni E 1, Tiribelli M 2, Zauli G1.
    Author information

    1 Department of Morphology and Embryology, University of Ferrara, Ferrara, Italy.
    2. Department of Medical and Morphological Research, Division of Hematology and Bone Marrow Transplantation, University Hospital, Udine, Italy.
    Corresponding Author: Giorgio Zauli, Department of Morphology and Embryology, University of Ferrara, Via Fossato di Mortara 66, 44100 Ferrara, Italy. Phone: 39-0532-455579; Fax: 39-0532-207351; E-mail: giorgio.zauli@unife.it.

    See: https://pubpeer.com/publications/99A80F13B01DEEF3AF0CB3D2D6AF6A

    Like

  31. Pingback: L'Università chiamata a decidere sul comportamento etico del suo rettore - Universitari Online

  32. Estense newspaper reports:
    L’Università chiamata a decidere sul comportamento etico del suo rettore
    Noto giornalista scientifico accusa Zauli di aver manipolato alcune sue ricerche accademiche, la replica: «Accuse del tutto infondate, prodotta documentazione per confutare quanto affermato»
    https://www.estense.com/?p=700352

    Like

  33. Zebedee

    The University of Ferrara should be able to conduct an investigation.
    The Catholic University School of Medicine, Roma (Rome) managed an investigation are requested several retractions.
    https://retractionwatch.com/2014/09/26/deceased-researcher-has-two-more-papers-retracted/

    “Following an internal investigation by the Catholic University School of Medicine, following a complaint on figure image manipulation, the Catholic University Commission confirmed the inappropriate figure assembly of Figure 2, panel A and B and Figure 5, panels A, C and E.”

    Surely the higher managers at the University of Ferrara could contact the higher managers at the Catholic University School of Medicine?

    Remember: the Pope is only infallible in matters of faith, not in matters temporal.

    Like

  34. Zebedee

    Cell Immunol. 2001 Feb 1;207(2):89-99.
    HIV-1 Tat Protects CD4+ Jurkat T Lymphoblastoid Cells from Apoptosis Mediated by TNF-Related Apoptosis-Inducing Ligand
    Author links open overlay panel
    DavideGibellini a
    Maria Carla Re a
    Cristina Ponti b
    Claudia Maldini a
    Claudio Celeghini b
    Alessandra Cappellini b
    Michele La Placa a
    GiorgioZauli b
    a Microbiology Section, Department of Clinical and Experimental Medicine, University of Bologna, Via Massarenti 9, 40138, Bologna
    b Department of Biomorphology, “G. d’Annunzio” University of Chieti, Via dei Vestini 6, 66100, Chieti, Italy.

    Figure 3.

    Like

    • Smut Clyde

      The unlikely similarity of the two lanes is particularly clear at higher contrast.

      Like

  35. Nix Recto

    Get him fired and dont be afraid of his absurd law suit, it won’t go anywhere.

    Like

  36. Zebedee

    Cancer Res. 1998 Feb 15;58(4):737-42.
    HLA class I antigen and transporter associated with antigen processing (TAP1 and TAP2) down-regulation in high-grade primary breast carcinoma lesions.
    Marco Vitale, Rita Rezzani, Luigi Rodella, Giorgio Zauli, Piergiovanni Grigolato, Moris Cadei, Daniel J. Hicklin, and Soldano Ferrone2
    Department of Biomedical Sciences and Biotechnologies, Human Anatomy Section, University of Brescia, 25123 Brescia, Italy [M. V., R. R., L. R.]; Institute of Cytomorphology N.P. CNR c/o Institute Codivilla-Putti, 40100 Bologna, Italy [M. R.]; Institute of Human Anatomy, University of Ferrara, 44100 Ferrara, Italy [G. Z.]; Pathology Laboratory, University of Brescia, Italy [P. G., M. C.]; and Department of Microbiology and Immunology, New York Medical College, Valhalla, New York 10595 [D. J. H., S. F.]

    Figure 3.

    Apart from a slight difference in cropping there are no convincing differences between 3B and 3C.
    It looks likes the same section of tissue. Usually people stain adjacent sections with different antibodies, not the same one with different ones.

    Like

  37. Zebedee

    http://lanuovaferrara.gelocal.it/ferrara/cronaca/2018/06/06/news/unife-la-commissione-etica-va-avanti-sugli-studi-di-zauli-1.16930648?refresh_ce

    6th June 2018 article.

    This might be old news, but the local newspaper has reported again.

    Ferrara, l’organismo emetterà un parere sulla possibilità di applicare il codice sul caso delle ricerche segnalate per “scorrettezza” da blogger e investigatori scientifici.

    “Ferrara, the body will issue an opinion on the possibility of applying the code on the case of research reported by “bloggers” by bloggers and scientific investigators.

    Like

  38. Zebedee

    Clin Cancer Res. 2011 Sep 1;17(17):5649-55. doi: 10.1158/1078-0432.CCR-11-1064. Epub 2011 Jul 13.
    Nutlin-3 downregulates the expression of the oncogene TCL1 in primary B chronic lymphocytic leukemic cells.
    Voltan R1, di Iasio MG, Bosco R, Valeri N, Pekarski Y, Tiribelli M, Secchiero P, Zauli G.
    Author information
    Department of Morphology and Embryology and LTTA Centre, University of Ferrara, Ferrara, Italy.

    Figures 2C and 4A.

    Like

  39. Zebedee

    Clin Cancer Res. 2013 Jul 15;19(14):3871-80. doi: 10.1158/1078-0432.CCR-13-0015. Epub 2013 May 29.
    Nanoparticles engineered with rituximab and loaded with Nutlin-3 show promising therapeutic activity in B-leukemic xenografts.
    Voltan R1, Secchiero P, Ruozi B, Forni F, Agostinis C, Caruso L, Vandelli MA, Zauli G.
    Author information

    1
    Department of Morphology, Surgery and Experimental Medicine and LTTA Centre, University of Ferrara, Ferrara, Italy.

    Like

  40. Zebedee

    Correction. Cell Cycle. 2012 Jul 1;11(13):2467-75.

    Figure 5A.

    Like

  41. Zebedee

    Correction Cell Cycle. 2012 Jul 1;11(13):2467-75. doi: 10.4161/cc.20859.

    Figure 5A.

    Like

  42. Zebedee

    Cell Cycle. 2012 Jul 1;11(13):2467-75. doi: 10.4161/cc.20859. Epub 2012 Jul 1.
    Activity of the selective IκB kinase inhibitor BMS-345541 against T-cell acute lymphoblastic leukemia: involvement of FOXO3a.
    Francesca Buontempo,1 Francesca Chiarini,2 Daniela Bressanin,3 Giovanna tabellini,4 Fraia Melchionda,5 Andrea pession,5 Milena Fini,1 Luca M. Neri,6 James A. McCubrey7 and Alberto M. Martelli2,3,*
    1Laboratory of preclinical and Surgical Studies; Rizzoli orthopedic Institute; Bologna, Italy; 2Institute of Molecular Genetics; National Research Council-Rizzoli orthopedic Institute; Bologna, Italy; 3Department of Human Anatomy; University of Bologna; Bologna, Italy; 4Department of Biomedical Sciences and Biotechnology; University of Brescia; Brescia, Italy; 5paediatric oncology and Hematology Unit Lalla Seràgnoli; University of Bologna; Bologna, Italy; 6Department of Morphology and embryology; University of Ferrara; Ferrara, Italy; 7Department of Microbiology & Immunology; Brody School of Medicine; east Carolina University; Greenville, NC USA.

    Figure 2A.

    Figure 3D.

    Figure 4.

    Figure 5A.

    Like

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: